Sanofi-Aventis in Lovenox PR hire

NEW YORK: Newly merged global pharma giant Sanofi-Aventis has appointed Euro RSCG Life to handle global PR, medical education and advertising for three of its drugs.

The PR element of the contract – which covers Lantus and Apidra, both treatments for diabetes, and Lovenox, a blood-thinner – will be handled by Euro RSCG Life NRP. The assignment covers 60 countries.

Although terms of the deal weren’t disclosed, the win places Sanofi-Aventis among the top five clients for Havas, the global advertising and comms services group that is Euro RSCG’s holding company.

Blockbuster Lovenox in particular has been a major revenue driver for the drugs giant, according to its latest earnings report.

Euro RSCG Life chief executive Ron Pantello said in a statement that the agency would focus on crafting a ‘unified, consistent’ message.

Sanofi-Aventis – formed from the merger of Sanofi-Synthelabo and Aventis earlier this year – unveiled the latest appointments to its global communications operation last month, with Charles Rouse at the helm in the US (PRWeek, 15 October).

Michel Joly has become vice-president of product PR, reporting to senior V-P of comms Nicole Cranois, who heads the France-headquartered pharma giant’s global comms function.

In other countries, Aventis’s Xavier Legrand du Laurens has become vice-president of comms for France, and Sanofi’s Miriam Henn is now vice-president of comms for Germany.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.